基线及他汀治疗中脂蛋白(a)水平对心血管事件的预测:他汀结局试验个体患者数据荟萃分析
结果显示两者呈近似线性独立关联,基线脂蛋白(a)≥30 mg/dL及他汀治疗中≥50 mg/dL时风险升高,为他汀治疗患者降脂蛋白(a)假说提供依据。
要点
- 基线脂蛋白(a)≥30 mg/dL与他汀治疗中≥50 mg/dL时心血管风险升高
- 他汀治疗中脂蛋白(a)与心血管风险的关联强于安慰剂,且年轻患者更明显
- 脂蛋白(a)与心血管风险呈独立近似线性关系,支持开展降脂蛋白(a)结局试验
核心结论
- 在他汀治疗患者中,基线及他汀治疗中升高的脂蛋白(a)与心血管疾病风险呈独立近似线性关系。
- 该研究为在心血管结局试验中检验降脂蛋白(a)假说提供了依据。
研究设计与样本
- 汇总7项随机、安慰剂对照的他汀结局试验的个体患者数据并进行协调。
- 按预设脂蛋白(a)分组(15至<30 mg/dL、30至<50 mg/dL、≥50 mg/dL,参照<15 mg/dL)在各试验内估计心血管事件的风险比,再用多变量随机效应荟萃分析合并。
主要发现
- 启动他汀治疗使LDL胆固醇平均降低39%(95%CI -43至-35),脂蛋白(a)无显著变化。
- 进一步校正既往心血管疾病、糖尿病、吸烟、收缩压、LDL胆固醇和HDL胆固醇后HR几乎相同。
关键数值与推荐
- 基线脂蛋白(a)≥30 mg/dL时心血管风险升高。
- 他汀治疗中脂蛋白(a)≥50 mg/dL时心血管风险升高。
临床怎么用
- 对于已接受他汀治疗的患者,可关注脂蛋白(a)水平以评估残余心血管风险。
- 基线脂蛋白(a)≥30 mg/dL或他汀治疗中≥50 mg/dL提示心血管风险升高,尤其年轻患者。
- 目前尚无降脂蛋白(a)改善心血管结局的证实,需等待结局试验结果。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated lipoprotein(a) is a genetic risk factor for cardiovascular disease in general population studies. However, its contribution to risk for cardiovascular events in patients with established cardiovascular disease or on statin therapy is uncertain. METHODS: Patient-level data from seven randomised, placebo-controlled, statin outcomes trials were collated and harmonised to calculate hazard ratios (HRs) for cardiovascular events, defined as fatal or non-fatal coronary heart disease, stroke, or revascularisation procedures. HRs for cardiovascular events were estimated within each trial across predefined lipoprotein(a) groups (15 to <30 mg/dL, 30 to <50 mg/dL, and ≥50 mg/dL, vs <15 mg/dL), before pooling estimates using multivariate random-effects meta-analysis. FINDINGS: Analyses included data for 29 069 patients with repeat lipoprotein(a) measurements (mean age 62 years [SD 8]; 8064 [28%] women; 5751 events during 95 576 person-years at risk). Initiation of statin therapy reduced LDL cholesterol (mean change -39% [95% CI -43 to -35]) without a significant change in lipoprotein(a). Associations of baseline and on-statin treatment lipoprotein(a) with cardiovascular disease risk were approximately linear, with increased risk at lipoprotein(a) values of 30 mg/dL or greater for baseline lipoprotein(a) and 50 mg/dL or greater for on-statin lipoprotein(a). For baseline lipoprotein(a), HRs adjusted for age and sex (vs <15 mg/dL) were 1·04 (95% CI 0·91-1·18) for 15 mg/dL to less than 30 mg/dL, 1·11 (1·00-1·22) for 30 mg/dL to less than 50 mg/dL, and 1·31 (1·08-1·58) for 50 mg/dL or higher; respective HRs for on-statin lipoprotein(a) were 0·94 (0·81-1·10), 1·06 (0·94-1·21), and 1·43 (1·15-1·76). HRs were almost identical after further adjustment for previous cardiovascular disease, diabetes, smoking, systolic blood pressure, LDL cholesterol, and HDL cholesterol. The association of on-statin lipoprotein(a) with cardiovascular disease risk was stronger than for on-placebo lipoprotein(a) (interaction p=0·010) and was more pronounced at younger ages (interaction p=0·008) without effect-modification by any other patient-level or study-level characteristics. INTERPRETATION: In this individual-patient data meta-analysis of statin-treated patients, elevated baseline and on-statin lipoprotein(a) showed an independent approximately linear relation with cardiovascular disease risk. This study provides a rationale for testing the lipoprotein(a) lowering hypothesis in cardiovascular disease outcomes trials. FUNDING: Novartis Pharma AG.
引用
- Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018. PMID: 30293769. doi:10.1016/S0140-6736(18)31652-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。